Dr. Li Wang 王莉
Chief Physician
Department of Gynecologic Oncology, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive diagnosis and treatment of gynecologic tumors, including cervical, ovarian, and uterine cancers. Specializes in complex tumor surgery and fertility-sparing radical trachelectomy for early-stage cervical cancer.
Dr. Wang is Director of the Gynecologic Oncology Department and the Henan Provincial Cervical Cancer Diagnosis and Treatment Center. Graduated from Henan Medical University in 1987. Completed a one-year fellowship at St George Hospital Cancer Centre, University of New South Wales, Australia, in 2007. Introduced DSA technology for early diagnosis of trophoblastic tumors in 2003. Leads six provincial and one national research project.
Professional roles
- Vice Chair, Gynecologic Oncology Professional Committee, Henan Branch, Chinese Medical Association
- Standing Committee Member, Obstetrics and Gynecology Professional Committee, Henan Branch, Chinese Medical Association
- Vice Chair, Gynecologic Oncology Branch, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Wang Li). Papers usually list the name as Li Wang or Wang L.
Selected publications
98 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Hemasphere, 2026 (first author): Zanubrutinib monotherapy in CD79B-mutated relapsed or refractory diffuse large B-cell lymphoma: A multicenter Phase 2 study. PubMed 42890318
- Mol Cell Probes, 2026 (senior author): Integration of PNA-mediated PCR and CRISPR/Cas13a for highly sensitive detection of EGFR T790M mutation in circulating tumor DNA. PubMed 42607937
- J Hematol Oncol, 2026 (first author): A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies. PubMed 42216090
- Biochem Biophys Res Commun, 2026 (senior author): UBE2C-orchestrated ubiquitination networks in cancer progression and therapy resistance. PubMed 41793850
- J Ovarian Res, 2025 (first author): A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC). PubMed 41408312
- Mol Biomed, 2025 (senior author): Clinicopathological characteristics, genetic aberrations, and optimized treatment strategies in double-hit and triple-hit lymphoma: a multi-center cohort study. PubMed 41364305
- Epigenetics, 2025 (senior author): Advancements in DNA methylation technologies and their application in cancer diagnosis. PubMed 40726108
- Clin Case Rep, 2025 (senior author): Incidentally Discovered Ovarian Cancer Combined With Obturator Nerve Schwannoma: A Rare Case Report. PubMed 41235385
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion